Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies

Journal of Gynecologic Oncology

Volumn 21, Issue 1, 2010, Pages 3-11

  Burger, Robert A ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Angiogenesis; Bevacizumab; Cervical neoplasms; Endometrial neoplasms; Ovarian neoplasms; Vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; GEMCITABINE; MOTESANIB; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PLACEBO; RAMUCIRUMAB; SORAFENIB; SUNITINIB; TOPOTECAN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ABSENCE OF SIDE EFFECTS; ARTERY THROMBOSIS; ARTICLE; ASCITES TUMOR; BRAIN ISCHEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CLINICAL TRIAL; COLORECTAL CANCER; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; EPISTAXIS; GYNECOLOGIC CANCER; HUMAN; HYPERTENSION; LUNG CANCER; MUCOSAL BLEEDING; OVARY CANCER; OVARY CARCINOMA; PANCREAS CANCER; PATHOGENESIS; PLEURA EFFUSION; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROTEIN TARGETING; PROTEINURIA; PULMONARY HYPERTENSION; RECURRENT CANCER; SIGNAL TRANSDUCTION; TREATMENT INDICATION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERUS CANCER;

EID: 77953412707     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2010.21.1.3     Document Type: Article

References (70)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigel C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-130
3. 3. Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, Hofmann JI, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003; 9: 5721-5728 (Pubitemid 37499496)
4. 4. Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T, Jaffe RB. Vascular endodielial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 2002; 161: 1917-1924 (Pubitemid 35265548)
5. 5. Luo JC, Toyoda M, Shibuya M. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res 1998; 58: 2594-2600 (Pubitemid 28275431)
6. 6. Luo JC, Yamaguchi S, Shinkai A, Shitara K, Shibuya M. Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors. Cancer Res 1998; 58: 2652-2660 (Pubitemid 28275440)
7. 7. Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 1998; 153: 1249-1256 (Pubitemid 28465848)
8. Urick ME, Giles JR, Johnson PA. VEGF expression and the effect of NSAIDs on ascites cell proliferation in the hen model of ovarian cancer. Gynecol Oncol 2008; 110: 418-424
9. 9. Verheul HM, Hoekman K, Joma AS, Smit EF, Pinedo HM. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist 2000; 5 Suppl 1: 45-50. (Pubitemid 30225457)
10. 10. Abularia O, Triest WE, Sherer DM. Angiogenesis in primary and metastatic epithelial ovarian carcinoma. Am J Obstet Gynecol 1997; 177: 541-547 (Pubitemid 27413766)
11. 11. Alvarez AA, Krigman HR, Whitaker RS, Dodge RK, Rodriguez GC. The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res 1999; 5: 587-591 (Pubitemid 29131968)
12. 12. Gasparini G, Bonoldi E, Viale G, Verderio P, Boracchi P, Panizzoni GA, et al. Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int J Cancer 1996; 69: 205-211 (Pubitemid 26233300)
13. Goodheart MJ, Ritchie JM, Rose SL, Fruehauf JP, De Young BR, Buller RE. The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clin Cancer Res 2005; 11: 3733-3742
14. Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML, Merino MJ. Tumor angiogenesis in advanced stage ovarian carcinoma. AmJ Pathol 1995; 147: 33-41.
15. 15. Chen CA, Cheng WF, Lee CN, Wei LH, Chu JS, Hsieh FJ, et al. Cytosol vascular endothelial growth factor in endometrial carcinoma: correlation with disease-free survival. Gynecol Oncol 2001; 80: 207-212 (Pubitemid 32158460)
16. Kaku T, Kamura T, Kinukawa N, Kobayashi H, Sakai K, Tsuruchi N, et al. Angiogenesis in endometrial carcinoma. Cancer 1997; 80: 741-747
17. 17. Obermair A, Tempfer C, Wasicky R, Kaider A, Hefler L, Kainz C. Prognostic significance of tumor angiogenesis in endometrial cancer. Obstet Gynecol 1999; 93: 367-371 (Pubitemid 29106994)
18. 18. Salvesen HB, Iversen OE, Akslen LA. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol 1999; 17: 1382-1390 (Pubitemid 29220843)
19. 19. Wagatsuma S, Konno R, Sato S, Yajima A. Tumor angiogenesis, hepatocyte growth factor, and c-Met expression in endometrial carcinoma. Cancer 1998; 82: 520-530 (Pubitemid 28112991)
20. 20. Bremer GL, Tiebosch AT, van der Putten HW, Schouten HJ, de Haan J, Arends JW Tumor angiogenesis: an independent prognostic parameter in cervical cancer. AmJ Obstet Gynecol 1996; 174: 126-131 (Pubitemid 26037700)
21. Cooper RA, Wilks DP, Logue JB Davidson SE, Hunter RD, Roberts SA, et al. High tumor angiogenesis is associated with poorer survival in carcinoma of the cervix treated with radiotherapy. Clin Cancer Res 1998; 4: 2795-2800
22. 22. Obermair A, Wanner C, Bilgi S, Speiser P, Raider A, Reinthaller A, et al. Tumor angiogenesis in stage IB cervical cancer: correlation of microvessel density with survival. AmJ Obstet Gynecol 1998; 178: 314-319 (Pubitemid 28124133)
23. 23. Ino K, Shibata K, Kajiyama H, Yamamoto E, Nagasaka T, Nawa A, et al. Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival. BrJ Cancer 2006; 94: 552-560 (Pubitemid 43289760)
24. 24. Paley PJ, Staskus KA, Gebhard K, Mohanraj D, Twiggs LB, Carson LF, et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 1997; 80: 98-106. (Pubitemid 27270925)
25. 25. Shen GH, Ghazizadeh M, Kawanami O, Shimizu H, Jin E, Araki T, et al. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 2000; 83: 196-203. (Pubitemid 30411717)
26. Huang S, Robinson JB, Deguzman A, Bucana CD, Fidler IJ. Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 2000; 60: 5334-5339
27. 27. Mu J, Abe Y, Tsutsui T, Yamamoto N, Tai XG, Niwa O, et al. Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity. Jpn J Cancer Res 1996; 87: 963-971 (Pubitemid 26328923)
28. Sher I, Adham SA, Petrik J, Coomber BL Autocrine VEGF-A/ KDR loop proteas epithelial ovarian carcinoma cells from anoikis. Int J Cancer 2009; 124: 553-561
29. Xu L, Yoneda J, Herrera C, Wood J, Killion JJ, Fidler IJ. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int J Oncol 2000; 16: 445-454
30. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
31. 31. Price DJ, Miralem T, Jiang S, Steinberg R, Avraham H. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ 2001; 12: 129-135 (Pubitemid 32677998)
32. Chen H, Ye D, Xie X, Chen B, Lu W. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecol Oncol 2004; 94: 630-635
33. 33. Fan F, Wey JS, McCarty MF, Belcheva A, Liu W, Bauer TW, et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 2005; 24: 2647-2653 (Pubitemid 40593092)
34. Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, Wright KA, et al. Expression of vascular endothelial growth factor and its receptors fit and KDR in ovarian carcinoma. J Nad Cancer Inst 1995; 87: 506-516
35. 35. Wu Y, Hooper AT, Zhong Z, Witte L, Bohlen P, Rafii S, et al. The vascular endodielial growth factor receptor (VEGFR-I) supports growth and survival of human breast carcinoma. Int J Cancer 2006; 119: 1519-1529 (Pubitemid 44258756)
36. Bevacizumab: anti-VEGF monoclonal antibody, avastin, rhumab-VEGF. Drugs R D 2002; 3: 28-30.
37. Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap Regeneran, VEGF Trap (R1R2), VEGF Trap-Eye. Drugs R D 2008; 9: 261-269
38. Krupitskaya Y, Wakelee HA. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Curr Opin Investig Drugs 2009; 10: 597-605.
39. Lindsay CR, MacPherson IR, Cassidy J. Current status of cediranib: the rapid development of a novel anti-angiogenic therapy. Future Oncol 2009; 5: 421-432
40. Sloan B, Scheinfeld NS. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr Opin Investig Drugs 2008; 9: 1324-1335
41. 41. Strumberg D. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc) 2005; 41: 773-784 (Pubitemid 43333354)
42. Izzedine H, Buhaescu I, Rixe O, Deray G. Sunitinib malate. Cancer Chemother Pharmacol 2007; 60: 357-364
43. AVSTIN (bevacizumab): Full prescribing information, including boxed warnings [Internet]. South San Francisco: Genentech Inc.; c2009 [cited 2010 Jan 20]. Available from: http://www. gene.com/gene/products/information/oncology/ avastin/insert.jsp.
44. US National Cancer Institute. Common toxicity criteria [Internet]. Bethesda: US National Cancer Institute; c2010 [cited 2010 Jan 20]. Available from: http://ctep.cancer.gav/protocolDevelopment/electronic-applications/ctc. htm.
45. US National Cancer Institute. Clinical trials [Internet]. Bethesda: US National Cancer Institute; c2010 [cited 2010 Jan 20]. Available from: http://www.cancer.gov/clinicaltrials.
46. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised REQST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247
47. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal caner: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25: 5165-5171
48. 48. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25: 5180-5186 (Pubitemid 350232248)
49. Aghajanian C, Sill MW, Darcy K, Greer B, McMeekin DS, Rose PG, et al. A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial caneen a Gynecologic Oncology Group (GOG) Study. J Clin Oncol 2009; 27(15S): abstr 5531.
50. Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2009; 27: 1069-1074
51. Tew WP, Colombo N, Ray-Coquard I, del Campo J, Scambia G, Spriggs D. VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC) : preliminary results of a randomized, multicenter phase n study. J Clin Oncol 2007; 25(18S): abstr 5508.
52. CNBC News [Internet]. Sanofi, regeneron cancer drug misses study goal (21 May 2008). Englewood Cliffs (NJ): CNBC Inc.; c2009 [cited 2008 May 21]. Available from: http://www.cnbc. com/id/24755167.
53. National Cancer Institute. Investigational Drug Branch, U.S. Department of Health & Human Services, Cancer Therapy Evaluation Program (CTEP): Bevacizumab IND action letter. Bethesda: National Cancer Institute; 2005.
54. Han ES, Monk BJ. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 2007; 105: 3-6.
55. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell ER Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544
56. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342
57. Miller KD, Chap LI, Holmes EA, Cobleigh MA, Marcom PK, Fahrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792-799
58. 58. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550 (Pubitemid 44917502)
59. Bidus MA, Webb JC, SeidmanJD, Rose GS, Boice CR, Elkas JC. Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms. Gynecol Oncol 2006; 102: 5-7.
60. 60. Burger RA. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 2007; 25: 2902-2908 (Pubitemid 47123154)
61. 61. Cohn DE, Valmadre S, Resnick KE, Eaton LA, Copeland LJ, Fowler JM. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol 2006; 102: 134-139 (Pubitemid 44056263)
62. 62. Monk BJ, Choi DC, Pugmire G, Burger RA. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2005; 96: 902-905 (Pubitemid 40255525)
63. 63. Monk BJ, Han E, Josephs-Cowan CA, Pugmire G, Burger RA. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2006; 102: 140-144 (Pubitemid 44056265)
64. Richardson DL, Backes FJ, Seamon LG, Zanagnolo V, O'Malley DM, Cohn DE, et al. Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol Oncol 2008; 111: 461-466
65. 65. Wright JD, Viviano D, Powell MA, Gibb RK, Mutch DG, Grigsby PW, et al. Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol 2006; 103: 489-493 (Pubitemid 44602157)
66. 66. Wright JD, Hagemann A, RaderJS, Viviano D, Gibb RK, Norris L, et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 2006; 107: 83-89 (Pubitemid 43939034)
67. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian caneen a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008; 26: 76-82.
68. 68. Micha JP, Goldstein BH, Rettenmaier MA, Genesen M, Graham C, Bader K, et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 2007; 17: 771-776 (Pubitemid 47063333)
69. Penson RT, Cannistra SA, Seiden MV, Krasner CN, Matulonis UA, Horowitz NS, et al. Phase II study of carboplatin, paditaxel and bevacizumab as first line chemotherapy and consolidation for advanced mullerian tumors. J Clin Oncol 2006; 24(18S): abstr 5020.
70. Nimeiri HS, Oza AM, Morgan RJ, Friberg G, Kasza K, Faoro L, et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 2008; 110: 49-55.